menu
    • menu
    [{"orgOrder":0,"company":"Evotec","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Chinook Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Borealis Biosciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery Platform","graph3":"Borealis Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nephrology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Borealis Biosciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Borealis Biosciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery Platform","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protalix BioTherapeutics \/ Secarna Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Protalix BioTherapeutics \/ Secarna Pharma"},{"orgOrder":0,"company":"Variant Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2026","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery Platform","graph3":"Variant Bio","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Variant Bio \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Variant Bio \/ Boehringer Ingelheim GmbH"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Variant Bio

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Variant Bio

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Discovery Platform

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $120.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Boehringer Expands Kidney Deal with $120M Variant Agreement

                            Details : The collaboration aims to advance research in Chronic Kidney Disease (CKD) with an undisclosed lead product.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 06, 2026

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Discovery Platform

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $120.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Protalix BioTherapeutics

                            Israel arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Protalix BioTherapeutics

                            Israel arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Discovery Platform

                            Sponsor : Secarna Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Protalix Biotherapeutics, Secarna Pharmaceuticals Collaborate and Option Agreement

                            Details : The collaboration aims to advance the development of an undisclosed oligonucleotide for renal diseases.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            December 17, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Discovery Platform

                            Sponsor : Secarna Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Borealis Biosciences

                            Canada arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Borealis Biosciences

                            Canada arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Versant Ventures and Novartis Launch Borealis Biosciences with $150 Million in Funding

                            Details : The company will use the proceeds to focus on discovering next-generation next-generation xRNA-based medicines for kidney diseases using xRNA technology platform innovation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 22, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evotec

                            Germany arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Evotec

                            Germany arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Discovery Platform

                            Sponsor : Chinook Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evotec and Chinook Therapeutics Enter Into Strategic Collaboration to Discover and Develop Novel Precision Med...

                            Details : The collaboration leverages Evotec’s proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with PanHunter, Evotec’s unique integrated data analysis platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 01, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Discovery Platform

                            Sponsor : Chinook Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.